2018 Oklahoma Society of Clinical Oncology (OSCO) Update from Spring/Summer Oncology Meetings

Saturday, September 15, 2018, 7:00 AM - 1:00 PM, AAT 1A/1B


The 2018 Oklahoma Society of Clinical Oncology (OSCO) Update from Spring/Summer Oncology Meetings will highlight the foremost research and strategies in oncology that were presented at the 2018 ASCO® Annual Meeting. Topics will include Neo and Post-op Adjuvant Therapy in Pancreatic Cancer, Advances in Combination Immunotherapies for Melanoma, Results of TAILORx (Trial Assigning Individualized Options for Treatment) and Advances in Lung Cancer. 

1. Explain and highlight the foremost research and strategies in oncology that were presented at the 2018 ASCO® Annual Meeting
2. Analyze broad topics that cover: Pallative, Supportive Care; Hematologic Malignancies, Lung Cancer/Thoracis, Gastronintestinal Cancers, New Therapeutics, and Gynecology Oncology.
3. State updated educational needs of Hematologists and Oncologist, Nurses, Pharmacists, Physician Assistants and other health care professionals specializing in Oncology.

Registration Fee:

Physicians—$75
Other Health Care Professionals—$25
Residents/Students - No Charge (call 405-271-2350 for online registration instructions)  

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Oklahoma College of Medicine and the Oklahoma Society of Clinical Oncology, Inc.  The University of Oklahoma College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Oklahoma College of Medicine designates this live activity for a maximum of 3.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Conflict Resolution Statement:

The University of Oklahoma College of Medicine, Office of Continuing Professional Development has
reviewed this activity’s speaker and planner disclosures and resolved all identified conflicts of interest, if applicable.

Activity Description

2018 Oklahoma Society of Clinical Oncology (OSCO) Update from Spring/Summer Oncology Meetings will highlight the foremost research and strategies in oncology that were presented at the 2018 ASCO® Annual Meeting. Topics will include Neo and Post-op Adjuvant Therapy in Pancreatic Cancer, Advances in Combination Immunotherapies for Melanoma, Results of TAILORx (Trial Assigning Individualized Options for Treatment) and Advances in Lung Cancer. 

Intended/Target Audience: 

Hematologists and Oncologists, Nurses, Pharmacists, Physician Assistants and other health care professionals specializing in Oncology.

Planning Committee Members:

William C. Dooley, MD, FACS, Course Director
Jose Eugenio Najera, MD
Mary K. Lindemuth, MD, PGY-4, Surgery Resident
Kathy Musson - Course Contact

Nondiscrimination Statement:

The University of Oklahoma, in compliance with all applicable federal and state laws and regulations, does not discriminate on the basis of race, color, national origin, sex, sexual orientation, genetic information, gender identity, gender expression, age, religion, disability, political beliefs, or status as a veteran in any of its policies, practices or procedures. This includes, but is not limited to: admissions, employment, financial aid and educational services. Inquiries regarding non-discrimination policies may be directed to: Bobby J. Mason, Institutional Equity Officer, (405) 325-3546, [email protected], or visit www.ou.edu/eoo.

Accommodation Statement:

Accommodations on the basis of disability are available by contacting Kathy Musson by phone at
(405) 850-8334 or by e-mail to [email protected] as soon as possible.

Disclaimer Statement:

Statements, opinions and results of studies contained in the program are those of the presenters, authors and joint provider and do not reflect the policy or position of the Board of Regents of the University of
Oklahoma (“OU”) nor does OU provide any warranty as to their accuracy or reliability.

Every reasonable effort has been made to faithfully reproduce the presentations and material as
submitted. However, no responsibility is assumed by OU for any claims, injury and/or damage to persons or property from any cause, including negligence or otherwise, or from any use or operation of any methods, products, instruments or ideas contained in the material herein.

Policy on Faculty, Joint Provider and Presenters Disclosure:

It is the policy of the University of Oklahoma, College of Medicine that the faculty, presenters and joint provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and
also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). 

Further Information is available by contacting Kathy Musson, Executive Director of the Oklahoma Society of Clinical Oncology, Inc. by e-mail at [email protected] or by phone at (405) 850-8334.

Accreditation Council for Graduate Medical Education (ACGME):
American Board of Medical Specialties (ABMS) Competencies:
Patient Care
Medical Knowledge

Parking information for attendees of the OSCO “Best of ASCO® Review”

Andrews Academic Tower Conference Center, Entrance off Stanton L. Young Blvd
Visitor/Events Parking available in Lot 11F.  Gate code available upon request.

OUHSC residents and staff are to park in their normal parking areas.

Oklahoma Society of Clinical Oncology, Inc.

The Oklahoma Society of Clinical Oncology, Inc. (OSCO) serves as the hub for oncology-related news and advances in Oklahoma. Our organization is made up of clinics and healthcare professionals working together to safeguard the rights of patients and to maintain high medical and ethical standards in the industry.OSCO Charter

• Advance the sciences of hematology and oncology and its sub-specialties and improve services to the public by studying the socio-economic aspects of the practice of its members. 
• Encourage improved educational opportunities for members. 
• Promote interchange between members.
• Safeguard the rights of patients with neoplastic diseases.
• Define the qualifications of physicians practicing hematology and oncology in Oklahoma. 
• Serve as spokesperson and liaison to governmental and insurance interests on behalf of its members. 
• Disseminate information regarding legislative and regulatory developments affecting the issues of common concern to members. 
• Promote scientific inquiry and exchange between members. 
• Establish and maintain high medical and ethical standards for members. 
• Promote good fellowship among its members.

AMA PRA Category 1 Credits™ (3.75 hours), Non-Physician Attendance (3.75 hours)

Planning Committee Members:

    William C. Dooley, MD  Dooley Bio
                         Course Director
                          Past President, Oklahoma Society of Clinical Oncology, Inc.
                          OU Medical Center, Dept of Surgery 

    Jose Eugenio Najera, MD   Najera Bio
                     President, Oklahoma Society of Clinical Oncology, Inc. 
                     Cancer Centers of Southwest Oklahoma

   Mary K. Lindemuth, MD  Lindemuth Bio
                    PGY-4, Surgery Resident

   Kathy Musson, CAE  Musson Bio
                 Course Contact 
                 Executive Director, Oklahoma Society of Clinical Oncology, Inc.

Planning committee disclosures and resolutions will be available in the course syllabus.

Speakers, Moderators, Authors, and Panelists:

Saturday, September 15, 2018

Acknowledgement of Commercial and In-Kind Support:

Commercial support is financial, or in-kind, contributions given by a commercial interest, which is used to pay all or part of the costs of a CME activity.  A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.

Appropriate acknowledgement of all commercial and in-kind support will be given at the time of the
educational activity.